J Hematol Oncol. 2011 Aug 2;4(1):32. doi: 10.1186/1756-8722-4-32.
Nilotinib is approved for treatment of newly diagnosed chronic myeloid leukemia (CML) and it is shown superiority over imatinib in first-line treatment for patients of CML. In this study, we established a nilotinib-resistant cell line, K562NR, and evaluated the resistance to nilotinib and efficacy of dasatinib. We found activation of Lyn plays a dominant role in survival of the nilotinib-resistant cell line. We found dasatinib induces the apoptosis of nilotinib-resistant cells and inhibits Lyn kinase activity. This novel nilotinib-resistant CML cell line may help to explore novel therapy for CML.
尼洛替尼已被批准用于治疗新诊断的慢性髓性白血病（CML），并且在 CML 患者的一线治疗中显示出优于伊马替尼的优势。在这项研究中，我们建立了尼洛替尼耐药细胞系 K562NR，并评估了对尼洛替尼的耐药性和达沙替尼的疗效。我们发现 Lyn 的激活在尼洛替尼耐药细胞系的存活中起主导作用。我们发现达沙替尼诱导尼洛替尼耐药细胞凋亡并抑制 Lyn 激酶活性。这种新型尼洛替尼耐药 CML 细胞系可能有助于探索 CML 的新治疗方法。
